EpiCept will receive approximately $4.7 million in net proceeds from the offering. Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group acted as placement agent.
EpiCept intends to use the net proceeds for general corporate purposes.
EpiCept will receive approximately $4.7 million in net proceeds from the offering. Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group acted as placement agent.
EpiCept intends to use the net proceeds for general corporate purposes.